If you need to take medicine to prevent tuberculosis, but you're already on other medications, you might worry about dangerous interactions or whether you'll be able to finish the treatment. A fresh look at data from a large trial offers some reassurance. The study focused on over 1,300 people taking rifampin to prevent TB. About one in five were also on other medications flagged as having a potential interaction with rifampin. The analysis found no difference between groups in who completed the full prevention course or who reported side effects. However, people taking those other medications were more than twice as likely to need two or more unscheduled doctor visits. It's important to remember this was a secondary look at existing trial data, not a study designed from the start to answer this question. The full details are only available in an abstract, so we're missing some context. While this is encouraging news for using rifampin safely with other common drugs, it clearly shows that closer monitoring and more follow-up appointments are a practical reality for these patients.
Photo by ilgmyzin / Unsplash
Do drug interactions make tuberculosis prevention harder to finish?
Plain Language Summary
What this means for you:
TB prevention with rifampin works with other meds, but expect more doctor visits. What this means for you:
TB prevention with rifampin works with other meds, but expect more doctor visits. View Original Abstract ↓
<sec><title>BACKGROUND</title>Rifamycin TB preventive treatment (TPT) is critical to TB elimination. However, clinicians may be reluctant to recommend it over concerns related to drug-drug interactions (DDI). In this secondary analysis of data from the 2R² randomised clinical trial (comparing standard dose rifampin to high-dose rifampin for TPT), we investigate if participants taking medications with potential rifampin DDI had similar TPT completion, safety, and follow-up visits compared to those without.</sec><sec><title>METHODS</title>Data on concomitant medications, adverse events, treatment completion, and follow-up visits were compared between participants with and without potential rifampin DDI. Analyses were conducted with R, reporting risk difference (RD) using g-computation with logistic regression.</sec><sec><title>RESULTS</title>282 of 1,368 participants (21%) were taking essential medications with potential rifampin DDI. There was no RD in TPT completion (RD 0.04 [95% confidence interval (CI): -0.02; 0.09]) or adverse events (RD 0.02 [95% CI: -0.01; 0.06]) between participants with and without these medications. Individuals talking medications with potential DDI had a higher percentage of two or more unscheduled visits (12%) compared to those not taking them (5%) ( = 0.0001).</sec><sec><title>CONCLUSION</title>In participants taking medications with potential rifampin DDI, rifampin TPT can be used safely without impacting completion rates. However, additional follow-up visits should be anticipated.</sec>.